Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 16/20 | 0.66 |
| ▸ | WEE1 | P30291 | 4/20 | 0.60 |
| ▸ | SRC | P12931 | 10/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.57 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PAK4 | O96013 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16287072 | 0.88 | SRC (0.59) | FGFR1WEE1SRCPDGFRBPDGFRA | |
| SCHEMBL16287869 | 0.81 | SRC (0.73) | FGFR1WEE1SRCPDGFRBPDGFRA | |
| SCHEMBL16287371 | 0.81 | SRC (0.74) | FGFR1WEE1SRCPDGFRBPDGFRA | |
| SCHEMBL6641103 | 0.80 | FGFR1 (0.85) | FGFR1WEE1SRCPDGFRBPDGFRA | |
| SCHEMBL16287539 | 0.80 | WEE1 (0.69) | FGFR1WEE1SRCPDGFRBPDGFRA | |
| SCHEMBL868129 | 0.80 | FGFR1 (1.00) | FGFR1WEE1SRCPDGFRBPDGFRA | |
| SCHEMBL25399236 | 0.79 | FGFR1 (0.71) | FGFR1WEE1SRCPDGFRBPDGFRA | |
| SCHEMBL16287166 | 0.79 | SRC (0.62) | FGFR1WEE1SRCPDGFRBPDGFRA | |
| SCHEMBL30618362 | 0.79 | FGFR1 (0.72) | FGFR1WEE1SRCPDGFRBPDGFRA | |
| SCHEMBL25398482 | 0.79 | FGFR1 (0.72) | FGFR1WEE1SRCPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630962-B2 | 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | HOSPITAL CLINIC DE BARCELONA (ES) | 2017-04-25 | — | — | US | claimed |
| EP-3008063-B1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INST QUÍMIC DE SARRIÁ CETS FUNDACIÓ PRIVADA (ES) | 2017-04-19 | — | — | EP | claimed |
| US-20160176866-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ, PRIVADA (ES) | 2016-06-23 | — | — | US | claimed |
| EP-3008063-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | Institut Químic de Sarriá CETS Fundació Privada (ES) | 2016-04-20 | — | — | EP | claimed |
| WO-2014198960-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA (ES) | 2014-12-18 | — | — | WO | claimed |
| EP-2813504-A1 | 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | Institut Quimic De Sarriá Cets, Fundació Privada (ES) | 2014-12-17 | — | — | EP | claimed |
| US-9630962-B2 | 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | HOSPITAL CLINIC DE BARCELONA (ES) | 2017-04-25 | — | — | US | disclosed |
| US-9630962-B2 | 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | HOSPITAL CLINIC DE BARCELONA (ES) | 2017-04-25 | — | — | US | disclosed |
| EP-3008063-B1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INST QUÍMIC DE SARRIÁ CETS FUNDACIÓ PRIVADA (ES) | 2017-04-19 | — | — | EP | disclosed |
| EP-3008063-B1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INST QUÍMIC DE SARRIÁ CETS FUNDACIÓ PRIVADA (ES) | 2017-04-19 | — | — | EP | disclosed |
| US-20160176866-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ, PRIVADA (ES) | 2016-06-23 | — | — | US | disclosed |
| US-20160176866-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ, PRIVADA (ES) | 2016-06-23 | — | — | US | disclosed |
| WO-2014198960-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA (ES) | 2014-12-18 | — | — | WO | disclosed |
| EP-2813504-A1 | 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | Institut Quimic De Sarriá Cets, Fundació Privada (ES) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813504-A1 | 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof | Institut Quimic De Sarriá Cets, Fundació Privada (ES) | 2014-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176866-A1 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | BCL6, BCL9, BCL3 | FGFR1 4256/4885WEE1 3036/4885SRC 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.